Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer

Mark M. Awad(Brigham and Women's Hospital), Ramaswamy Govindan(Washington University in St. Louis), Kristen N. Balogh(BioNTech (United States)), David R. Spigel(Tennessee Oncology), Edward B. Garon(University of California, Los Angeles), Meghan E. Bushway(BioNTech (United States)), Asaf Poran(BioNTech (United States)), Joong Hyuk Sheen(BioNTech (United States)), Victoria Kohler(BioNTech (United States)), Ekaterina Esaulova(BioNTech (United States)), John Srouji(BioNTech (United States)), Suchitra Ramesh(BioNTech (United States)), Rohit Vyasamneni(BioNTech (United States)), Binisha Karki(University of California, Los Angeles), Tracey Sciuto(BioNTech (United States)), Himanshu Sethi(Natera (United States)), Jesse Z. Dong(BioNTech (United States)), Melissa A. Moles(BioNTech (United States)), Kelledy Manson(BioNTech (United States)), Michael S. Rooney(BioNTech (United States)), Zakaria Khondker(BioNTech (United States)), Mark DeMario(BioNTech (United States)), Richard B. Gaynor(BioNTech (United States)), Lakshmi Srinivasan(BioNTech (United States))
Cancer Cell
August 25, 2022
Cited by 219

Abstract


Related Papers